Contact this trialFirst, we need to learn more about you.
Tyrosine Kinase Inhibitor
Sutetinib for Non-Small Cell Lung Cancer
Recruiting1 awardPhase 2
New Hyde Park, New York
This trial will study a new drug to treat lung cancer in people with uncommon EGFR mutations.
Fill-in a few details and create your profileSave answers to your profile & unlock recommendations.
We will keep your details privateWe won't share unless you give us permission. By completing this form you agree to our privacy policy and terms of service
Get in touch with the study teamWe’ll send your responses to the study team and help you to setup your first screening. This is not the start of informed consent. Screening happens between you and the trial.
By clicking start, you agree to our
terms of service